MedTrace Logo

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07297329 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2026-01-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Conditions

  • Multiple Myeloma (MM)

Interventions

DRUG

SCTC21C

Pharmaceutical form: Solution for infusion； Route of administration: Subcutaneous

DRUG

Bortezomib

Pharmaceutical form: Lyophilized powder for injection； Route of administration: Subcutaneous

DRUG

Lenalidomide

Pharmaceutical form: Capsules； Route of administration: Oral

DRUG

Dexamethasone

Pharmaceutical form: Tablets, ampoules or vials for injection； Route of administration: Oral/Intravenous

Sponsors & Collaborators

  • Sinocelltech Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-29
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07297329 on ClinicalTrials.gov